Last update 08 May 2025
Astellas Pharma, Inc.

Astellas Pharma, Inc.

Public Company|2005|Tokyo-to, Japan|
10,000-50,000
| TYO: 4503|

Overview

Basic Info

Introduction
Astellas Pharma Inc. is a pharmaceutical company with a global presence. The company's core products include anticancer agents, treatments for overactive bladder, and immunosuppressants for organ transplantation. Astellas' competitiveness stems from its innovative R&D and extensive network, which includes cutting-edge technology gained through collaborations with academia, bio-ventures, and pharmaceutical companies worldwide. Astellas has implemented the "Focus Area Approach" as its R&D strategy, focusing on building sustainable and expandable drug discovery by selecting the best combination of biology, modality/technology, and disease. The company has identified four prioritized research areas: Blindness & Regeneration, Mitochondria Biology, Genetic Regulation, and Immuno-Oncology, named "Primary Focus" where it strategically expands its pipeline. Collaborations with academic labs and various pharmaceutical companies, including start-ups, are a key focus for Astellas. Dedicated teams have been assigned to maximize the value of these collaborations, including Astellas Innovation Management, Business Development, and Astellas Venture Management.

Tags

Other Diseases
Neoplasms
Skin and Musculoskeletal Diseases
Small molecule drug
AAV based gene therapy
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug82
AAV based gene therapy15
Monoclonal antibody10
Cell therapy5
Antibody drug conjugate (ADC)5

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
12
58
Preclinical
Phase 1 Clinical
17
12
Phase 2 Clinical
Phase 3 Clinical
5
48
Approved
Other
560
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free